Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

被引：0
|
作者：
Yu, Qiuxia [1 ]
Zhang, Xiaoying [2 ]
Wang, Na [1 ]
Huang, Liang [1 ]
Li, Chunrui [3 ]
Zhang, Yicheng [1 ]
Zhou, Jianfeng [4 ]
Wang, Gaoxiang [1 ]
Cao, Yang [4 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165174
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：10311 / 10312
页数：2
相关论文
共 50 条
  • [31] Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T-cell pathway in patients with diffuse large B-cell lymphoma
    Lolli, Ginevra
    Argnani, Lisa
    Gini, Guido
    Casadei, Beatrice
    Pellegrini, Cinzia
    Tani, Monica
    Pavone, Vincenzo
    Cimminiello, Michele
    Bonifazi, Francesca
    Zinzani, Pier Luigi
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (05) : 947 - 950
  • [32] Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas
    Anagha Deshpande
    William Rule
    Allison Rosenthal
    Current Treatment Options in Oncology, 2022, 23 : 89 - 98
  • [33] Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas
    Deshpande, Anagha
    Rule, William
    Rosenthal, Allison
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (01) : 89 - 98
  • [34] Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma
    Kenta Hayashino
    Keisuke Seike
    Kanako Fujiwara
    Kaho Kondo
    Chisato Matsubara
    Toshiki Terao
    Wataru Kitamura
    Chihiro Kamoi
    Hideaki Fujiwara
    Noboru Asada
    Hisakazu Nishimori
    Daisuke Ennishi
    Keiko Fujii
    Nobuharu Fujii
    Ken-ichi Matsuoka
    Yoshinobu Maeda
    International Journal of Hematology, 2024, 119 : 459 - 464
  • [35] Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
    Lin, Richard J.
    Lobaugh, Stephanie M.
    Pennisi, Martina
    Chan, Hei Ton
    Batlevi, Yakup
    Ruiz, Josel D.
    Elko, Theresa A.
    Maloy, Molly A.
    Batlevi, Connie L.
    Dahi, Parastoo B.
    Hamlin, Paul A.
    Giralt, Sergio A.
    Hamlin, Paul A.
    Mead, Elena
    Noy, Ariela
    Palomba, M. Lia
    Santomasso, Bianca D.
    Sauter, Craig S.
    Scordo, Michael
    Shah, Gunjan L.
    Korc-Grodzicki, Beatriz
    Kim, Soo Jung
    Silverberg, Mari Lynne
    Brooklyn, Chelsea A.
    Devlin, Sean M.
    Perales, Miguel-Angel
    HAEMATOLOGICA, 2021, 106 (01) : 255 - 258
  • [36] Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy
    Weinstock, Matt
    Elavalakanar, Pavania
    Bright, Susan
    Ambati, Srikanth R.
    Brouwer-Visser, Jurriaan
    Pourpe, Stephane
    Fiaschi, Nathalie
    Jankovic, Vladimir
    Thurston, Gavin
    Deering, Raquel P.
    Chaudhry, Aafia
    Joyce, Robin
    Arnason, Jon
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (03) : 366 - 370
  • [37] Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma
    Hayashino, Kenta
    Seike, Keisuke
    Fujiwara, Kanako
    Kondo, Kaho
    Matsubara, Chisato
    Terao, Toshiki
    Kitamura, Wataru
    Kamoi, Chihiro
    Fujiwara, Hideaki
    Asada, Noboru
    Nishimori, Hisakazu
    Ennishi, Daisuke
    Fujii, Keiko
    Fujii, Nobuharu
    Matsuoka, Ken-ichi
    Maeda, Yoshinobu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 119 (04) : 459 - 464
  • [38] CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma
    Gideon, Jacklyn
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (06) : 597 - 601
  • [39] Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options
    Toro-Mijares, Raul Del
    Oluwole, Olalekan
    Jayani, Reena V.
    Kassim, Adetola A.
    Savani, Bipin N.
    Dholaria, Bhagirathbhai
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (01) : 15 - 24
  • [40] An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
    Xue Bin
    Liu Yifan
    Zhang Min
    Xiao Gangfeng
    Luo Xiu
    Zhou Lili
    Ye Shiguang
    Lu Yan
    Qian Wenbin
    Wang Li
    Li Ping
    Liang Aibin
    中华医学杂志英文版, 2025, 138 (01)
12345